Nemonapride

This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q88T5P3444, chemically known as n-(2rs,3rs)-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide but generally known as nemonapride, which bears US NIH Compound Identifier 156333. European Medicines Agency schedules Nemonapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09191MIG. The term NEMONAPRIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). NEMONAPRIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule nemonapride under HS 29339990 and SITC 51577. As of Q4 2014, NEMONAPRIDE remains the US FDA Preferred Term for this commodity. Nemonapride bears US NLM identifiers UMLS ID C0217937 and NCI Concept Code C73036. SMILES: CLC1CC(C(=O)NC2C(N(CC2)CC2CCCCC2)C)C(OC)CC1NC.